The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen administered subcutaneously to Healthy Volunteers

Inclusion Criteria:

• Must have given written informed consent and be able to comply with all study requirements
• Healthy males or females aged 18-65 inclusive at the time of Informed Consent
• Females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal
• Males must be surgically sterile, abstinent or using an acceptable contraceptive method
• BMI <35 kg/m2

Exclusion Criteria:

• Clinically-significant abnormalities in medical history including acute coronary syndrome, major surgery within 3 months of Screening, planned surgery that would occur during the study or physical examination or other screening results such as ECGs at Screening
• Clinically significant hematologic, chemistry, and urine abnormalities
• Treatment with another Study Drug, biological agent, or device within 4 weeks of Screening
• History of bleeding diathesis or coagulopathy
• Smoking >10 cigarettes per day
• Considered unsuitable for inclusion by the Principal Investigator
• Current use of concomitant medications (including herbal or OTC medications) unless approved by Sponsor Medical Monitor
• Known history or positive test for HIV, hepatitis C or chronic hepatitis B
• Blood donation within 30 days of screening